LENZ logo

LENZ Therapeutics, Inc.

LENZ
Healthcare|Biotechnology|US
$3.50
+0.49 (+16.28%)
DCF Value
$2.33
Tangible Book / Share
$6.11
Cash / Share
$6.28
Next Earnings Report
Mar 23, 2027
EPS est. -$0.82 · Revenue est. $4.0M
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.

Upcoming Data Readouts (1)

Aug 2029
Est. completion
NABreast Cancer
Effects of Neoadjuvant Prehabilitation on Post-Interventional Physical and Psychological Outcomes in Oncology Patients With Solid Tumors
NCT07464457n=125

Recent Press Releases

LENZ Therapeutics Reports Third Quarter 2026 Financial Results, Announces Strategic Consumer Marketing Focused Reorganization and CEO Succession
Oct 28, 2026 · GlobeNewsWire
LENZ Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026
Oct 22, 2026 · GlobeNewsWire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
Oct 6, 2026 · GlobeNewsWire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
Oct 1, 2026 · PRNewsWire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
Sep 29, 2026 · GlobeNewsWire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
Sep 24, 2026 · PRNewsWire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
Sep 22, 2026 · GlobeNewsWire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
Sep 17, 2026 · PRNewsWire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
Sep 15, 2026 · GlobeNewsWire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
Sep 10, 2026 · PRNewsWire

SEC Filings (72)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 5, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Nov 4, 2026SC 13GPassive 5%+ stakeDocumentIndex
Nov 3, 202610-QQuarterly reportDocumentIndex
Nov 2, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
Oct 28, 20268-KMaterial eventDocumentIndex
Oct 27, 2026SC 13GPassive 5%+ stakeDocumentIndex
Oct 21, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Sep 8, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 11, 202610-QQuarterly reportDocumentIndex
Aug 11, 20268-KMaterial eventDocumentIndex
Jul 2, 20268-KMaterial eventDocumentIndex
Jun 26, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jun 12, 20268-KMaterial eventDocumentIndex
May 11, 202610-QQuarterly reportDocumentIndex
May 11, 20268-KMaterial eventDocumentIndex
Apr 28, 2026ARSAnnual report to holdersDocumentIndex
Apr 28, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 28, 2026DEF 14AProxy / shareholder voteDocumentIndex
Apr 27, 2026SC 13GPassive 5%+ stakeDocumentIndex
Apr 8, 2026SC 13GPassive 5%+ stakeDocumentIndex
Mar 24, 2026S-8Employee stock planDocumentIndex
Mar 24, 202610-KAnnual reportDocumentIndex
Mar 24, 20268-KMaterial eventDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 5, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jan 21, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jan 7, 20268-KMaterial eventDocumentIndex
Dec 12, 20258-KMaterial eventDocumentIndex
Nov 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Nov 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Nov 10, 2025SC 13D/AActivist / 5%+ stakeDocumentIndex
Nov 7, 2025SC 13D/AActivist / 5%+ stakeDocumentIndex
Nov 7, 2025SC 13GPassive 5%+ stakeDocumentIndex
Nov 5, 202510-QQuarterly reportDocumentIndex
Nov 5, 20258-KMaterial eventDocumentIndex
Oct 17, 2025SC 13GPassive 5%+ stakeDocumentIndex
Oct 8, 20258-KMaterial eventDocumentIndex
Sep 30, 20258-KMaterial eventDocumentIndex
Sep 22, 2025SC 13D/AActivist / 5%+ stakeDocumentIndex
Aug 20, 2025SC 13D/AActivist / 5%+ stakeDocumentIndex